Biolidics Statistics

Total Valuation

Biolidics has a market cap or net worth of SGD 38.89 million. The enterprise value is 40.34 million.

Market Cap	38.89M
Enterprise Value	40.34M

Important Dates

The next estimated earnings date is Friday, May 2, 2025.

Earnings Date	May 2, 2025
Ex-Dividend Date	n/a

Share Statistics

Biolidics has 1.69 billion shares outstanding. The number of shares has increased by 65.44% in one year.

Current Share Class	n/a
Shares Outstanding	1.69B
Shares Change (YoY)	+65.44%
Shares Change (QoQ)	+36.55%
Owned by Insiders (%)	50.47%
Owned by Institutions (%)	2.85%
Float	818.37M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	26.32
PB Ratio	37.58
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.75
EV / Sales	47.02
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-58.38

Financial Position

The company has a current ratio of 0.26, with a Debt / Equity ratio of 1.69.

Current Ratio	0.26
Quick Ratio	0.25
Debt / Equity	1.69
Debt / EBITDA	n/a
Debt / FCF	-2.53
Interest Coverage	-81.67

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-85.67%
Return on Invested Capital (ROIC)	-141.18%
Return on Capital Employed (ROCE)	-228.48%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	15
Asset Turnover	0.37
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +100.00% in the last 52 weeks. The beta is 0.33, so Biolidics's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	+100.00%
50-Day Moving Average	0.02
200-Day Moving Average	0.02
Relative Strength Index (RSI)	44.94
Average Volume (20 Days)	1,106,865

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biolidics had revenue of SGD 858,000 and -3.43 million in losses. Loss per share was -0.00.

Revenue	858,000
Gross Profit	306,000
Operating Income	-3.19M
Pretax Income	-3.19M
Net Income	-3.43M
EBITDA	-3.18M
EBIT	-3.19M
Loss Per Share	-0.00

Full Income Statement

Balance Sheet

The company has 295,000 in cash and 1.75 million in debt, giving a net cash position of -1.46 million or -0.00 per share.

Cash & Cash Equivalents	295,000
Total Debt	1.75M
Net Cash	-1.46M
Net Cash Per Share	-0.00
Equity (Book Value)	1.04M
Book Value Per Share	0.00
Working Capital	-1.90M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -685,000 and capital expenditures -6,000, giving a free cash flow of -691,000.

Operating Cash Flow	-685,000
Capital Expenditures	-6,000
Free Cash Flow	-691,000
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross Margin	35.66%
Operating Margin	-371.21%
Pretax Margin	-371.45%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Biolidics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-65.44%
Shareholder Yield	-65.44%
Earnings Yield	-8.83%
FCF Yield	-1.78%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biolidics has an Altman Z-Score of -25.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-25.92
Piotroski F-Score	n/a